A5003105021- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Biosimilars and Bioanalytical Methods
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Methemoglobinemia and Tumor Lysis Syndrome
- Genetic factors in colorectal cancer
- Acute Myeloid Leukemia Research
- Vascular Tumors and Angiosarcomas
- Erythropoietin and Anemia Treatment
- Neutropenia and Cancer Infections
Hospices Civils de Lyon
2010-2020
Hôpital Lyon Sud
2010-2019
Université Claude Bernard Lyon 1
2009-2018
Centre de Recherche en Cancérologie de Lyon
2016-2018
Université Paris Cité
2006-2018
Inserm
1989-2018
Peter MacCallum Cancer Centre
2018
Mayo Clinic
2018
Saarland University
2018
Université de Rouen Normandie
2018
The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in lymphoma. We conducted randomized trial to compare CHOP chemotherapy plus rituximab alone elderly
Purpose Standardized response criteria are needed to interpret and compare clinical trials for approval of new therapeutic agents by regulatory agencies. Methods The International Working Group (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because identified limitations the increased use [ 18 F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), flow cytometry. Harmonization Project was convened provide updated...
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses. In this report we describe prospective randomized study of such treatment.
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies acceptable side-effect profiles needed for this patient population. In multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor delta isoform phosphatidylinositol 3-kinase, in combination rituximab versus plus placebo. We...
Purpose To analyze the long-term outcome of patients included in Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) elderly with diffuse large B-cell lymphoma. Patients Methods LNH98-5 was a randomized that 399 previously untreated patients, age 60 80 years, received eight cycles classical (cyclophosphamide 750 mg/m 2 , doxorubicin 50 vincristine 1.4 40 for 5 days) every 3 weeks. In R-CHOP,...
Temsirolimus, a specific inhibitor of the mammalian target rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens temsirolimus comparison with investigator's choice single-agent therapy relapsed or refractory disease.In this multicenter, open-label, phase III study, 162 patients MCL were randomly assigned (1:1:1) to receive one regimens: 175 mg weekly for 3 weeks followed by either 75 (175/75-mg) 25 (175/25-mg) weekly, from prospectively...
Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).Patients who were at least one prior systemic therapy for whom failed received 14 mg/m(2) as 4-hour intravenous infusion on days 1, 8, and 15 every 28 days. end point rate complete response/unconfirmed...
Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's with no accepted standard care. This study evaluated the efficacy and tolerability pralatrexate, novel antifolate promising activity.Patients independently confirmed PTCL who progressed following ≥ 1 line prior therapy received pralatrexate intravenously at 30 mg/m(2)/wk for 6 weeks in 7-week cycles. Primary assessment response was made by independent central review using International Workshop Criteria. The...
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most have a relapse. We investigated whether fludarabine-containing induction regimen improved the complete-remission rate maintenance therapy rituximab prolonged remission.We randomly assigned 60 years age or lymphoma, stage II to IV, who were not eligible high-dose six cycles rituximab, fludarabine, cyclophosphamide (R-FC) every 28 days eight...
PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic (SLL) are malignancies that express CD20 incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity overall response rates (RR) complete (CR) rituximab (chimeric anti-CD20 monoclonal antibody). PATIENTS AND METHODS: Between January 1997 1998, 131 patients newly diagnosed MCL (MCL1; n = 34) previously treated (MCL2; 40), IMC (n 28), SLL 29) received 375 mg/m 2 /wk for...
PURPOSE: To present the final analysis, with a median follow-up of 8 years, LNH87–2 randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine) high-dose therapy (HDT) using cyclophosphamide, carmustine, etoposide (CBV regimen) followed by stem-cell transplantation in patients aggressive non-Hodgkin’s lymphoma first complete remission after induction, focusing on high/intermediate- high-risk identified age-adjusted...
PURPOSE Characteristics and outcome of 108 patients with mucosa-associated lymphoid tissue (MALT) lymphoma were analyzed according to initial location the lymphoma, within or outside gastrointestinal (GI) tract. PATIENTS AND METHODS One hundred eight MALT studied. Fifty-five (51%) had GI involvement 53 (49%) another involved extranodal site: 13 orbit; 11 lung; 10 skin; seven parotid; six thyroid; three Waldeyer's ring; two breast; one pancreas involvement. At diagnosis, 47 (44%) stage IE, 26...
The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas.Angioimmunoblastic lymphoma (AITL) diagnosed according 2001 WHO criteria by a central review process consisting panels expert hematopathologists. Clinical, pathologic, immunophenotyping, treatment, survival data were correlated.Of 1,314 patients, 243 (18.5%) with AITL. At presentation, generalized lymphadenopathy noted in 76% 89% had stages...